Extended Data Fig. 10: Haematopoietic CSF1 deletion protects against haematopoiesis and atherosclerosis in hypocretin-deficient mice.

a, Schematic of chimeric models. b, c, Quantification of Ly-6C^high monocytes and neutrophils in blood (b; n = 4 WT;bmWT mice; n = 6 Hcrt^−/−;bmWT mice; n = 3 WT;bmCsf1^−/− mice; n = 5 Hcrt^−/−;bmCsf1^−/− mice) and bone marrow (c; n = 4 WT;bmWT mice; n = 6 Hcrt^−/−;bmWT mice; n = 3 WT;bmCsf1^−/− mice; n = 5 Hcrt^−/−;bmCsf1^−/− mice). d, Quantification of the number of LSK cells (n = 4 WT;bmWT mice; n = 6 Hcrt^−/−;bmWT mice; n = 3 WT;bmCsf1^−/− mice; n = 5 Hcrt^−/−;bmCsf1^−/− mice) and proliferation (n = 4 WT;bmWT mice; n = 4 Hcrt^−/−;bmWT mice; n = 3 WT;bmCsf1^−/− mice; n = 5 Hcrt^−/−;bmCsf1^−/− mice) in bone marrow. e, Quantification of CMPs, GMPs and MDPs in chimeric mice (n = 4 WT;bmWT mice; n = 6 Hcrt^−/−;bmWT mice; n = 3 WT;bmCsf1^−/− mice; n = 5 Hcrt^−/−;bmCsf1^−/− mice). f, Bone marrow CSF1 levels (n = 4 WT;bmWT mice; n = 8 Hcrt^−/−;bmWT mice; n = 4 WT;bmCsf1^−/− mice; n = 7 Hcrt^−/−;bmCsf1^−/− mice). g, Schematic of chimeric models receiving Adv-PCSK9 and fed a HCD for 12 weeks. h, Plasma cholesterol levels (n = 7 WT;bmWT mice; n = 10 Hcrt^−/−;bmWT mice; n = 5 WT;bmCsf1^−/− mice; n = 6 Hcrt^−/−;bmCsf1^−/− mice). i, Images of cross-sections of aortic roots stained with oil red O and quantification of atherosclerosis in chimeric mice (n = 7 WT;bmWT mice; n = 9 Hcrt^−/−;bmWT mice; n = 5 WT;bmCsf1^−/− mice; n = 6 Hcrt^−/−;bmCsf1^−/− mice). Data are mean ± s.e.m., *P < 0.05, **P < 0.01, ***P < 0.001, one-way ANOVA.